AstraZeneca and insitro Sign AI-Powered Drug Discovery Agreement
Pharmaceutical giant AstraZeneca has signed an agreement worth up to $1.5 billion with insitro for AI-based target discovery.
AstraZeneca has entered into a $1.5 billion AI collaboration with insitro, which includes an upfront payment of $40 million, aimed at discovering new drug targets for liver and heart diseases.
Details of the AI-Powered Agreement
AstraZeneca will make an upfront payment of $40 million to insitro to find new drug targets for liver and heart diseases using artificial intelligence. The agreement covers payments of up to $1.46 billion across development and commercial milestones.
Types of Diseases Focused On
Within the scope of this collaboration, the insitro platform will be applied to prevalent diseases such as metabolic dysfunction-associated steatohepatitis, known as MASH, and cardiomyopathies.
Global Rights and Future Plans
AstraZeneca will hold worldwide exclusive rights to advance selected programs emerging from this partnership. Insitro CEO Daphne Koller stated that this partnership could accelerate the process.